Our work suggests the feasibility of an ARE/SUZ12-regulated TK/GCV system for selectively eliminating BP-CML cells, suggesting that suicide gene engineering may be an effective strategy for treating BP-CML. This evidence concerns the gene TKT and chronic myelogenous leukemia, BCR-ABL1 positive.